trial

Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia

NCTId NCT01431092
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 86 (actual)
Sponsored by Lone Baandrup
Primary completion 2014-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
86 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-10
Primary completion
2014-06
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Melatonin

Sponsors

Lone BaandrupLead Sponsor
Glostrup University Hospital, CopenhagenCollaborator
Copenhagen Trial Unit, Center for Clinical Intervention ResearchCollaborator

Investigators

2
Lone Baandrup, MD, PhDPrincipal Investigator
Birte Glenthøj, ProfessorStudy Chair

Sites

1 total
Glostrup Municipality, Denmark

Facts & assertions

4 sourced
Enrollment
86
Phase
PHASE4
Primary Completion Date
2014-06
Status
COMPLETED
relationships
The graph out of here
drug
Melatonin
drug
lead_sponsor
Lone Baandrup
company
collaborator
Glostrup University Hospital, Copenhagen
company
Copenhagen Trial Unit, Center for Clinical Intervention Research
company
indication
Bipolar Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Lone Baandrup, MD, PhD
person
Birte Glenthøj, Professor
person